[go: up one dir, main page]

MX2015007082A - Métodos de administración de composiciones que comprenden ácido docosapentanoico. - Google Patents

Métodos de administración de composiciones que comprenden ácido docosapentanoico.

Info

Publication number
MX2015007082A
MX2015007082A MX2015007082A MX2015007082A MX2015007082A MX 2015007082 A MX2015007082 A MX 2015007082A MX 2015007082 A MX2015007082 A MX 2015007082A MX 2015007082 A MX2015007082 A MX 2015007082A MX 2015007082 A MX2015007082 A MX 2015007082A
Authority
MX
Mexico
Prior art keywords
administration
methods
compositions
docosapentanoic acid
cholesterol
Prior art date
Application number
MX2015007082A
Other languages
English (en)
Inventor
George Bobotas
Abdel Aziz Fawzy
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Publication of MX2015007082A publication Critical patent/MX2015007082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B20/00—Preservation of edible oils or fats
    • A23B20/30—Preservation of other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B5/00—Preserving by using additives, e.g. anti-oxidants
    • C11B5/0007—Organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)

Abstract

La presente invención se refiere a métodos para reducir parámetros lipídicos, tales como triglicéridos, colesterol total, colesterol de lipoproteína de baja densidad (LDL), no-HDL colesterol, ácidos grasos libres y otros lípidos, que comprende la administración de ácido omega-3 docosapentanoico.
MX2015007082A 2012-12-06 2013-12-06 Métodos de administración de composiciones que comprenden ácido docosapentanoico. MX2015007082A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734331P 2012-12-06 2012-12-06
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/073714 WO2014089511A2 (en) 2012-12-06 2013-12-06 Methods of administering compositions comprising docosapentaenoic acid

Publications (1)

Publication Number Publication Date
MX2015007082A true MX2015007082A (es) 2016-01-12

Family

ID=50884050

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007082A MX2015007082A (es) 2012-12-06 2013-12-06 Métodos de administración de composiciones que comprenden ácido docosapentanoico.
MX2015007085A MX2015007085A (es) 2012-12-06 2013-12-06 Composiciones de acido omega-3 pentanoico y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015007085A MX2015007085A (es) 2012-12-06 2013-12-06 Composiciones de acido omega-3 pentanoico y metodos de uso.

Country Status (9)

Country Link
EP (3) EP2928462A4 (es)
JP (4) JP2016501249A (es)
KR (3) KR20150103009A (es)
CN (4) CN112107570A (es)
AU (7) AU2013354969A1 (es)
CA (2) CA2894183A1 (es)
IN (2) IN2015MU01505A (es)
MX (2) MX2015007082A (es)
WO (2) WO2014089501A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101568665B1 (ko) 2015-07-21 2015-11-12 디와이오토 주식회사 모터의 맥동 전류를 증가시키는 브러시 구조
US20190346459A1 (en) * 2016-06-28 2019-11-14 Nestec S.A. Biomarkers of blood-brain barrier dysfunction
JP2018168139A (ja) * 2016-10-21 2018-11-01 マルハニチロ株式会社 ｎ−３系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるｎ−３系不飽和脂肪酸の使用
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002125618A (ja) * 2000-10-30 2002-05-08 Katsuyuki Wakatsuki 健康食品
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
WO2008004900A1 (en) * 2006-07-05 2008-01-10 Photonz Corporation Limited Production of ultrapure epa and polar lipids from largely heterotrophic culture
KR100684642B1 (ko) * 2006-09-14 2007-02-22 주식회사 일신웰스 어유 유래 글리세라이드 유지 조성물 및 이의 제조방법
KR102118478B1 (ko) * 2009-03-09 2020-06-04 바스프 에이에스 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물, 및 이의 방법 및 용도
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
SG10201605794PA (en) * 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
CN108096209A (zh) * 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
JP2014505732A (ja) * 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患において用いるための、スタチンおよびω３脂肪酸（ＥＰＡ、ＤＨＡおよびＤＰＡ）
EP2675442A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
CA2916208A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Also Published As

Publication number Publication date
KR20150103009A (ko) 2015-09-09
IN2015MU01505A (es) 2016-05-27
KR20150103671A (ko) 2015-09-11
JP2016501248A (ja) 2016-01-18
CA2894366A1 (en) 2014-06-12
EP2928462A4 (en) 2016-06-01
CN112107570A (zh) 2020-12-22
EP2929041A4 (en) 2016-06-08
AU2017232203A1 (en) 2017-10-12
AU2018229440A1 (en) 2018-10-04
JP2021120407A (ja) 2021-08-19
AU2013354979A1 (en) 2015-06-11
EP3888646A1 (en) 2021-10-06
AU2021201865A1 (en) 2021-04-22
KR20210059779A (ko) 2021-05-25
EP2929041A1 (en) 2015-10-14
JP2019172697A (ja) 2019-10-10
CN113274378A (zh) 2021-08-20
IN2015DE05009A (es) 2015-12-18
CN104902888A (zh) 2015-09-09
CN104937103A (zh) 2015-09-23
WO2014089511A3 (en) 2014-07-31
JP2016501249A (ja) 2016-01-18
MX2015007085A (es) 2016-01-12
JP6881893B2 (ja) 2021-06-02
WO2014089511A2 (en) 2014-06-12
AU2020203658A1 (en) 2020-06-25
CA2894183A1 (en) 2014-06-12
AU2019216634A1 (en) 2019-09-05
AU2013354969A1 (en) 2015-06-11
EP2928462A2 (en) 2015-10-14
WO2014089501A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
MX372724B (es) Formulaciones de acido eicosapentaenoico (epa).
CL2019003105A1 (es) Lípidos extraídos de plantas que comprenden ácidos grasos poliinsaturados de cadena larga. (divisional solicitud 201601560)
EA201400152A1 (ru) Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
MX2015007082A (es) Métodos de administración de composiciones que comprenden ácido docosapentanoico.
IN2014MN01673A (es)
UY35537A (es) Compuestos de amida sustituida
MY172796A (en) Nutritional compositions containing structured fat globules and uses thereof
EA201590026A1 (ru) Выработка длинноцепочечных полиненасыщенных жирных кислот в растительных клетках
CY1117616T1 (el) Διαδικασια για την απομονωση φωσφολιπιδιου
CL2012001124A1 (es) Composición farmacéutica que comprende un extracto terapéutico concentrado, que comprende fosfolípidos en concentración de 60 a 99% y uso para tratar enfermedades cardiovasculares, reducir niveles de triglicérido, reducir colesterol ldl y aumentar colesterol hdl.
NZ747847A (en) Lipid compositions
BR112014013593A2 (pt) retenção de dha durante o processamento de óleo de canola
MX374738B (es) Aceite oxidativamente estable que contiene acidos grasos poliinsaturados.
WO2012119781A3 (en) Novel lipids, phospholipids, phospholipid and lipid compositions and their use
BR112014009333A2 (pt) processo para produzir um éster de ácido graxo epoxidizado a partir de uma gordura ou óleo natural epoxidizado
UY36346A (es) Compuestos de amida sustituida
ECSP15021231A (es) Proceso de fabricación de biocarburantes
MX347400B (es) Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
EA201692398A1 (ru) Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол
GB2505830A (en) Dispersion of triglycerides
AR116761A2 (es) Lípido que comprende ácidos grasos poliinsaturados de cadena larga
BR112019000462A2 (pt) método para isolar lipídios de células contendo lipídio
BR112019000435A2 (pt) método para separar lipídios de uma biomassa contendo lipídios lisados